Literature DB >> 26300029

Development of New Psychopharmacological Agents for Depression and Anxiety.

Alan F Schatzberg1.   

Abstract

Antidepressant and anxiolytic drug development has largely stalled. This article reviews novel current programs for developing depressants and anxiolytics. Biological bases are discussed for these, as are recent results. Problems encountered are reviewed. Recently announced failed programs for other antidepressants are then discussed with an eye toward uncovering possible common elements that may explain their failures. Lastly, possible solutions for improving the likelihood of the success of antidepressant/anxiolytic agents are discussed.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antidepressants; Anxiolytics; Glucocorticoid antagonists; Glutamatergic agents; Ketamine; Mu-opioid agents; NMDA antagonists; Obotulinum toxin

Mesh：

Substances：

Year:  2015        PMID： 26300029     DOI： 10.1016/j.psc.2015.05.009

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN： 0193-953X


  7 in total

Review 1.  Herbal medicine for depression and anxiety: A systematic review with assessment of potential psycho-oncologic relevance.

Authors:  K Simon Yeung; Marisol Hernandez; Jun J Mao; Ingrid Haviland; Jyothirmai Gubili
Journal:  Phytother Res       Date:  2018-02-21       Impact factor: 5.878

Review 2.  Hormonal Treatments for Major Depressive Disorder: State of the Art.

Authors:  Jennifer B Dwyer; Awais Aftab; Rajiv Radhakrishnan; Alik Widge; Carolyn I Rodriguez; Linda L Carpenter; Charles B Nemeroff; William M McDonald; Ned H Kalin
Journal:  Am J Psychiatry       Date:  2020-05-27       Impact factor: 18.112

3.  MiR-129-5p prevents depressive-like behaviors by targeting MAPK1 to suppress inflammation.

Authors:  Jie Chang; Yanhong Zhang; Nianhong Shen; Jingquan Zhou; Huan Zhang
Journal:  Exp Brain Res       Date:  2021-09-04       Impact factor: 1.972

4.  Meranzin Hydrate Improves Depression-Like Behaviors and Hypomotility via Ghrelin and Neurocircuitry.

Authors:  Ya-Lin Liu; Jian-Jun Xu; Lin-Ran Han; Xiang-Fei Liu; Mu-Hai Lin; Yun Wang; Zhe Xiao; Yun-Ke Huang; Ping Ren; Xi Huang
Journal:  Chin J Integr Med       Date:  2022-07-26       Impact factor: 2.626

5.  Neural Signaling of Cortisol, Childhood Emotional Abuse, and Depression-Related Memory Bias.

Authors:  Heather C Abercrombie; Carlton P Frost; Erin C Walsh; Roxanne M Hoks; M Daniela Cornejo; Maggie C Sampe; Allison E Gaffey; David T Plante; Charlotte O Ladd; Rasmus M Birn
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-11-22

Review 6.  Schisandra chinensis Fructus and Its Active Ingredients as Promising Resources for the Treatment of Neurological Diseases.

Authors:  Minyu Zhang; Liping Xu; Hongjun Yang
Journal:  Int J Mol Sci       Date:  2018-07-06       Impact factor: 5.923

7.  Overexpression of microRNA-301b accelerates hippocampal microglia activation and cognitive impairment in mice with depressive-like behavior through the NF-κB signaling pathway.

Authors:  Chao-Zhi Tang; Dong-Fang Zhang; Jun-Tang Yang; Qing-Hui Liu; Ya-Ru Wang; Wen-Sheng Wang
Journal:  Cell Death Dis       Date:  2019-04-08       Impact factor: 8.469
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.